Journal Watch · Clinical Pharmacology & Therapeutics · 2026

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development.

This distinction raises a central question: how can causality be consistently represented, inferred, and validated across modeling approaches, and what is required to integrate them to support robust and credible decision-making?

Klabunde T, Hernandez R, van der Graaf PH, Andreani TClinical Pharmacology & Therapeutics3 min readPharma relevance 75/100

DOI: 10.1002/cpt.70486PMID: 42775694Study type: clinical study

TL;DR

This distinction raises a central question: how can causality be consistently represented, inferred, and validated across modeling approaches, and what is required to integrate them to support robust and credible decision-making?

Key findings

  • These paradigms reflect fundamentally different representations of causality-mechanism-driven versus data-driven-two complementary lenses on the same underlying goal of understanding and predicting intervention effects.
  • This distinction raises a central question: how can causality be consistently represented, inferred, and validated across modeling approaches, and what is required to integrate them to support robust and credible decision-making?

What they did

As such, QSP addresses the question: given specified mechanistic assumptions, how does the system behave under intervention? Complementing this mechanistic lens, causal inference approaches start from observed data and estimate the effects of interventions using formal causal frameworks and comparative outcome analysis. These methods explicitly address confounding, multicausality, and clinical heterogeneity, asking instead: given the data, what are the causal effects of intervening in the real world?

Full abstract (original)

Background: Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision-making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitative systems pharmacology (QSP) and causal inference (CI), two complementary paradigms that, together, address different but interlocking aspects of causal reasoning in drug development: one grounded in mechanistic simulation, the other in data-driven estimation. Mechanistic quantitative systems pharmacology (QSP) models generate physiologically interpretable predictions by encoding biological knowledge-such as compartmental flows, receptor kinetics, and feedback loops-typically in systems of differential equations.

What they did: As such, QSP addresses the question: given specified mechanistic assumptions, how does the system behave under intervention? Complementing this mechanistic lens, causal inference approaches start from observed data and estimate the effects of interventions using formal causal frameworks and comparative outcome analysis. These methods explicitly address confounding, multicausality, and clinical heterogeneity, asking instead: given the data, what are the causal effects of intervening in the real world?

Results & conclusions: These paradigms reflect fundamentally different representations of causality-mechanism-driven versus data-driven-two complementary lenses on the same underlying goal of understanding and predicting intervention effects. This distinction raises a central question: how can causality be consistently represented, inferred, and validated across modeling approaches, and what is required to integrate them to support robust and credible decision-making?

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70486 · PubMed 42775694.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Clinical Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

This distinction raises a central question: how can causality be consistently represented, inferred, and validated across modeling approaches, and what is required to integrate them to support robust and credible decision-making?

What type of study is this?

It is a clinical study, published in Clinical Pharmacology & Therapeutics in 2026. As such, QSP addresses the question: given specified mechanistic assumptions, how does the system behave under intervention?

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70486. PubMed ID: 42775694. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Klabunde T, Hernandez R, van der Graaf PH, Andreani T. From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70486.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/from-biological-mechanisms-to-causal-inference-quantitative-systems-phar-t70486/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides